t(9;22)(q34;q11) BCR/ABL1 in CML
2000-10-01 Ali G Turhan   Affiliation1.Translational Research - Cell Therapy, Laboratory, INSTITUT GUSTAVE ROUSSY, INSERM U. 362, 1 - 39, rue Camille Desmoulins, 94805 VILLEJUIF CEDEX - FRANCE
2.Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France
Clinics and Pathology
Disease
CML: all CML have a t(9;22), at least at the molecular level (seebelow); but not all t(9;22) are found in CML, as already noted
Phenotype stem cell origin
Evidence exists for the involvement of the most primitive and quiescent hematopoietic stem cell compartiment (CD34+/CD38-, Thy1+): t(9;22) is found in myeloid progenitor and in B-lymphocytes progenitors, but, involvement of the T-cell lineage is extremely rare
Epidemiology
annual incidence: 10/106 (from 1/106 in childhood to 30/106after 60 yrs); median age: 30-60 yrs; sex ratio: 1.2M/1F
Clinics
splenomegaly; chronic phase (lasts about 3 yrs) with maintained cells normal activities, followed by accelerated phase(s) (blasts still < 15%), and blast crisis (BC-CML) with blast cells > 30%; blood data: WBC: 100 X 109/l and more during chronic phase, with basophilia; a few blasts; thrombocytosis may be present; low leucocyte alkaline phosphatases; typical acute leukaemia (AL) blood data at the time of myeloid or lymphoid -type blast crisis
Cytology
hyperplastic bone marrow; granulocytes proliferation, with maturation; followed by typical AL cytology (see t(9;22)(q34;q11)/AML, and t(9;22)(q34;q11)/ALL)
Treatment
aIFN therapy or allogeneic bone marrow transplantation (BMT), donor leukocytes infusions
Prognosis
median survival: 4 yrs with conventional therapy (hydroxyurea, busulfan), 6 yrs with aIFN therapy; allogeneic bone marrow transplantation may cure the patient; otherwise, the best treatment to date associates interferon a, hydroxyurea and cytarabine
Cytogenetics
Cytogenetics morphological
the chromosomal anomaly persists during remission, in contrast with acute leukemia (AL) cases
Cytogenetics molecular
is a useful tool for diagnostic ascertainment in the case of a masked Philadelphia chromosome, where chromosomes 9 and 22 all appear to be normal, but where cryptic insertion of 3 ABL within a chromosome 22 can be demonstrated
Additional anomalies
1. may be present at diagnosis (in 10%, possibly with unfavourable significance), or may appear during course of the disease, they do not indicate the imminence of a blast crisis, although these additional anomalies also emerge frequently at the time of acute transformation;
2. these are: +der(22), +8, i(17q), +19, most often, but also: +21, -Y, -7, -17, +17; acute transformation can also be accompanied with t(3;21) (q26;q22) (1% of cases); near haploidy can occur; of note, although rare, is the occurrence of chromosome anomalies which are typical of a given BC phenotype (e.g. t(15;17) in a promyelocytic transformation, dic(9;12) in a CD10+ lymphoblastic BC ...); +8, +19, +21, and i(17q) occur more often in myeloid -rather than lymphoid- blast crises
2. these are: +der(22), +8, i(17q), +19, most often, but also: +21, -Y, -7, -17, +17; acute transformation can also be accompanied with t(3;21) (q26;q22) (1% of cases); near haploidy can occur; of note, although rare, is the occurrence of chromosome anomalies which are typical of a given BC phenotype (e.g. t(15;17) in a promyelocytic transformation, dic(9;12) in a CD10+ lymphoblastic BC ...); +8, +19, +21, and i(17q) occur more often in myeloid -rather than lymphoid- blast crises
Variants
t(9;22;V) and apparent t(V;22) or t(9;V), where V is a variable chromosome, are found in 5-10% of cases; however, 9q34-3ABL always joins 22q11-5BCR in true CML; the third chromosome and breakpoint is, at times, not random. In a way, masked Philadelphia chromosomes (see above) are also variants.

835J22 + 1132H12 and 72M14 Cohybridization of (835J22 + 1132H12; ABL) and 72M14 (BCR) on a CML patient carrying the t(9;22) translocation. Note the splitting of (835J22 + 1132H12) (red signal) and the colocalization on Ph chromosome (Ph) -Courtesy Mariano Rocchi, Resources for Molecular Cytogenetics

Cryptic insertion of BCR within chromosome 9. FISH using the Vysis LSI BCR/ABL Dual Color, Dual Fusion Translocation Probe - Courtesy Karolien Beel, Geneviu00e8ve Ameye and Lucienne Michaux, CME, UZ Leuven
Genes Involved and Proteins
Gene name
ABL1 (v-abl Abelson murine leukemia viral oncogene homolog 1)
Location
9q34.12
Dna rna description
alternate splicing (1a and 1b) in 5
Protein description
giving rise to 2 proteins of 145 kDa; contains SH (SRC homology) domains; N-term SH3 and SH2 - SH1 (tyrosine kinase) - DNA binding motif - actin binding domain C-term; widely expressed; localisation is mainly nuclear; inhibits cell growth
Gene name
BCR (Breakpoint cluster region)
Location
22q11.23
Dna rna description
various splicings
Protein description
main form: 160 KDa; N-term Serine-Treonine kinase domain, SH2 binding, and C-term domain which functions as a GTPase activating protein for p21rac; widely expressed; cytoplasmic localisation; protein kinase; probable role in signal transduction
Result of the Chromosomal Anomaly
Description
1. the crucial event lies on der(22), id est 5 BCR/3 ABL hybrid gene is pathogenic, while ABL/BCR may or may not be expressed;
2. breakpoint in ABL is variable over a region of 200 kb, often between the two alternative exons 1b and 1a, sometimes 5 of 1b, or 3 of 1a, but always 5 of exon 2;
3. breakpoint in BCR is in a narrow region, therefore called M-bcr (for major breakpoint cluster region), a cluster of 5.8 kb, between exons 12 and 16, also called b1 to b5 of M-bcr; most breakpoints being either between b2 and b3, or between b3 and b4
2. breakpoint in ABL is variable over a region of 200 kb, often between the two alternative exons 1b and 1a, sometimes 5 of 1b, or 3 of 1a, but always 5 of exon 2;
3. breakpoint in BCR is in a narrow region, therefore called M-bcr (for major breakpoint cluster region), a cluster of 5.8 kb, between exons 12 and 16, also called b1 to b5 of M-bcr; most breakpoints being either between b2 and b3, or between b3 and b4
Transcript
8.5 kb mRNA, resulting in a 210 KDa chimeric protein
Detection protocole
RT-PCR for minimal residual disease detection
Description
P210 with the first 902 or 927 amino acids from BCR; BCR/ABL has a cytoplasmic localization, in contrast with ABL, mostly nuclear. It is now clearly established that BCR-ABL is the oncogene responsible for the occurrence of CML . The hybrid protein has an increased protein kinase activity compared to ABL: 3BP1 (binding protein) binds normal ABL on SH3 domain, which prevents SH1 activation; with BCR/ABL, the first (N-terminal) exon of BCR binds to SH2, hidding SH3 which, as a consequence, cannot be bound to 3BP1; thereof, SH1 is activated
Oncogenesis
Highly cited references
| Pubmed ID | Year | Title | Citations |
|---|---|---|---|
| 35057108 | 2022 | BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia. | 188 |
| 38542279 | 2024 | Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia. | 131 |
| 42051376 | 2026 | BCR-ABL1 Drives Transcriptional Reprogramming of Chronic Myeloid Leukemia Cells for Immune Evasion Through C/EBPβ. | 113 |
| 37129698 | 2023 | Philadelphia-like acute lymphoblastic leukemia: the journey from molecular background to the role of bone marrow transplant-review article. | 101 |
| 37337105 | 2023 | Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia. | 91 |
| 38550948 | 2023 | Targeting BCR-ABL1-positive leukaemias: a review article. | 88 |
| 41373445 | 2025 | Chronic Myeloid Leukemia and the T315I BCR::ABL1 Mutation. | 85 |
| 38653245 | 2024 | Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia. | 83 |
| 41764406 | 2026 | BCR::ABL1-Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B-ALL Cells to Enhancer-Targeting Drugs. | 81 |
| 37629188 | 2023 | Diagnosis- and Prognosis-Related Gene Alterations in BCR::ABL1-Negative Myeloproliferative Neoplasms. | 80 |
| 35809644 | 2022 | Allosteric enhancement of the BCR-Abl1 kinase inhibition activity of nilotinib by cobinding of asciminib. | 73 |
| 31801582 | 2019 | Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper. | 72 |
| 33054045 | 2020 | BCR-ABL1-like acute lymphoblastic leukemia in childhood and targeted therapy. | 69 |
| 38397221 | 2024 | Frequencies of BCR::ABL1 Transcripts in Patients with Chronic Myeloid Leukemia: A Meta-Analysis. | 67 |
| 37397496 | 2023 | BCR-ABL1-positive acute lymphoblastic leukemia following successful treatment of acute promyelocytic leukemia: case report. | 61 |
| 33172063 | 2020 | Standardization of BCR-ABL1 p210 Monitoring: From Nested to Digital PCR. | 55 |
| 35551463 | 2022 | BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro. | 51 |
| 28707321 | 2017 | Expansion of BCR/ABL1(+) cells requires PAK2 but not PAK1. | 44 |
| 37400842 | 2023 | BCR::ABL1-like acute lymphoblastic leukaemia: a single institution experience on identification of potentially therapeutic targetable cases. | 41 |
| 28698860 | 2017 | Genomic Profiling of Chronic Myelogenous Leukemia: Basic and Clinical Approach. | 41 |
| 39214096 | 2024 | Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy. | 34 |
| 35361036 | 2022 | Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia. | 23 |
| 34485806 | 2021 | Report of Canonical BCR-ABL1 Fusion in Glioblastoma. | 21 |
| 33814500 | 2021 | BCR/ABL1-positive B-lymphoblastic Lymphoma Successfully Treated with Dasatinib-combined Chemotherapy. | 20 |
| 30125955 | 2018 | Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UK. | 19 |
| 36518237 | 2022 | BCR-ABL1 is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia. | 18 |
| 28983061 | 2018 | BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib. | 16 |
| 38750137 | 2024 | Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1. | 15 |
| 37621071 | 2023 | Co-existence of RUNX1-RUNX1T1 and BCR-ABL1 in acute myeloid leukemia: a case report. | 15 |
| 38879610 | 2024 | The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to asciminib. | 15 |
| 39085402 | 2024 | Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib. | 15 |
| 36348635 | 2022 | Detection of NUP214-ABL1 translocation using BCR-ABL1 dual color FISH probes in T-cell acute lymphoblastic leukemia-an illustrative report and review of literature. | 15 |
| 41053078 | 2025 | BCR::ABL1-positive acute lymphoblastic leukemia as a high-risk feature of central nervous system relapse after allogeneic hematopoietic cell transplantation. | 14 |
| 37407456 | 2024 | High Efficacy and Safety of Asciminib in a Chronic Myeloid Leukemia Patient with Chronic Kidney Disease Following Renal Transplantation. | 14 |
| 34758608 | 2022 | Detection of ABL1 kinase domain mutations in therapy-naïve BCR-ABL1-positive acute lymphoblastic leukemia. | 13 |
| 35699277 | 2022 | Initial Rate of BCR::ABL1 Decline for Response Prediction in Chronic Myeloid Leukemia. | 13 |
| 38879611 | 2024 | Point-of-care BCR::ABL1 transcript monitoring using capillary dried blood in chronic myeloid leukemia patients. | 13 |
| 35112716 | 2022 | BCR::ABL1 transcripts and clinical outcome - interrogating the technique. | 11 |
| 41163576 | 2026 | CML-like biology: BCR::ABL1 and beyond. | 10 |
| 36843408 | 2023 | Emergence of BCR-ABL1 (p190) in Acute Myeloid Leukemia Post-Gilteritinib Therapy. | 9 |
| 29552278 | 2018 | Cytogenetic alterations in CML: not all created equal. | 8 |
| 22210326 | 2012 | The other Achilles' heel of BCR-ABL1. | 6 |
| 27630861 | 2016 | No Benefit of BCR-ABL1 Screening in Polycythemia. | 5 |
| 32211287 | 2020 | Molecular responses in e19a2 BCR-ABL1 chronic myeloid leukemia. | 5 |
| 39932124 | 2025 | BCR::ABL1-Positive Acute Myeloid Leukemia. | 2 |
| 38604819 | 2024 | Chronic myeloid leukaemia: Biology and therapy. | 0 |
| 32908250 | 2020 | Declaration of Bcr-Abl1 independence. | 0 |
| 26869304 | 2016 | BCR-ABL1 mutation ≠ ponatinib resistance. | 0 |
| 30370478 | 2018 | Chronic Myeloid Leukemia: Beyond BCR-ABL1. | 0 |
| 28381535 | 2017 | Double trouble for CML. | 0 |
| 30561755 | 2019 | BCR/ABL1-like acute lymphoblastic leukemia: How to diagnose and treat? | 0 |
| 26843045 | 2016 | Digital PCR: Principles and Applications. | 0 |
| 32270699 | 2020 | Basic knowledge on BCR-ABL1-positive extracellular vesicles. | 0 |
| 33038988 | 2020 | CML - Not only BCR-ABL1 matters. | 0 |
| 36636958 | 2023 | BCR::ABL1-positive chronic myeloid leukaemia with CALR mutation. | 0 |
| 37548333 | 2023 | BCR-ABL1 co-occurring with CBFA2T3-GLIS2 and RAM immunophenotype in a non-Down syndrome infant with acute megakaryoblastic leukemia. | 0 |
| 30991025 | 2019 | γ-Catenin-Dependent Signals Maintain BCR-ABL1(+) B Cell Acute Lymphoblastic Leukemia. | 0 |
| 34818644 | 2022 | BCR/ABL1-Like Acute Lymphoblastic Leukemia: From Diagnostic Approaches to Molecularly Targeted Therapy. | 0 |
| 24131888 | 2014 | Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. | 0 |
| 32200189 | 2020 | Novel therapeutic approaches in chronic myeloid leukemia. | 0 |
| 39303728 | 2024 | Triplet therapy for advanced BCR::ABL1 positive myeloid leukaemias. | 0 |
| 31069976 | 2019 | BCR-ABL1-like B-lymphoblastic leukemia/lymphoma: Review of the entity and detection methodologies. | 0 |
| 37449465 | 2023 | Posttreatment positivity of BCR::ABL1 in acute lymphoblastic leukemia: Should we keep track? | 0 |
| 34608829 | 2021 | Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. | 0 |
| 34038034 | 2021 | Suspected chronic myeloid leukemia-like BCR-ABL1-positive acute lymphoblastic leukemia. | 0 |
| 36652997 | 2023 | Immunobiology of cytomegalovirus infection in patients with haematological malignancies undergoing treatment with small molecule inhibitors. | 0 |
| 36958819 | 2023 | BCR::ABL1 screening is not indicated in patients with splenomegaly without neutrophilia and/or basophilia. | 0 |
| 37302352 | 2023 | Genetic alterations in the BCR-ABL1 fusion gene related to imatinib resistance in chronic myeloid leukemia. | 0 |
| 34496460 | 2022 | BCR::ABL1-positive histiocytic sarcoma of the small intestine in a patient with chronic myeloid leukaemia. | 0 |
| 35267003 | 2022 | Pseudo-Chédiak-Higashi inclusions in BCR::ABL1-like B-lymphoblastic leukemia with IGH::EPOR rearrangement. | 0 |
| 38860593 | 2024 | Atypical BCR-ABL1 transcript in mixed phenotype acute leukemia with bone marrow necrosis. | 0 |
| 28222016 | 2017 | A review of the challenge in measuring and standardizing BCR-ABL1. | 0 |
| 35562492 | 2022 | Subclonal acquisition of a BCR::ABL1 fusion in a chronic myelomonocytic leukemia. | 0 |
| 38769689 | 2024 | BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: An individual participant data meta-analysis. | 0 |
| 37969054 | 2024 | BCR::ABL1 fusion gene positive de novo acute myeloid leukemia with coexistence of NRAS mutation and presented with a peculiar CD58 positive immunophenotype. | 0 |
| 19002192 | 2008 | BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features. | 0 |
| 37871900 | 2024 | IGJ and SPATS2L immunohistochemistry sensitively and specifically identify BCR::ABL1+ and BCR::ABL1-like B-acute lymphoblastic leukaemia. | 0 |
| 26208040 | 2016 | BCR-ABL1 b3a2 and b2a2 transcripts in chronic myeloid leukemia: does it matter? | 0 |
| 34725711 | 2022 | Acute Promyelocytic Leukemia with a BCR-ABL1 Rearrangement in a Minor Clone. | 0 |
| 31595038 | 2020 | In Ph+BCR-ABL1(P210+) acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent. | 0 |
| 36156725 | 2022 | [BCR-ABL1 negative chronic myeloid leukemia: report of two cases]. | 0 |
| 39316990 | 2024 | Strategies to overcome splicing variants interference in mutational testing for BCR::ABL1 KD. | 0 |
| 35021069 | 2022 | Development of asciminib, a novel allosteric inhibitor of BCR-ABL1. | 0 |
| 25895547 | 2015 | BCR/ABL1 Kinase Domain Mutation Monitoring: Could Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Benefit As Well? | 0 |
| 24627518 | 2014 | Refining prognosis in BCR-ABL1-positive ALL. | 0 |
| 30938769 | 2019 | BCR-ABL1-like B-Lymphoblastic Leukemia/Lymphoma with FOXP1-ABL1 Rearrangement: Comprehensive Laboratory Identification Allowing Tyrosine Kinase Inhibitor Use. | 0 |
| 37530356 | 2023 | Identification of rare atypical BCR-ABL1 transcript: A case report. | 0 |
| 41034052 | 2025 | [Mechanisms of resistance to the allosteric BCR::ABL1 inhibitor asciminib]. | 0 |
| 28663031 | 2017 | Mutational analysis in BCR-ABL1 positive leukemia by deep sequencing based on nanopore MinION technology. | 0 |
| 25573033 | 2015 | Managing children with chronic myeloid leukaemia--response to Baccarani. | 0 |
| 29508536 | 2018 | Chronic myeloid leukemia, BCR-ABL1-positive with CALR and MPL mutations. | 0 |
| 26637844 | 2015 | Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia. | 0 |
| 35389507 | 2022 | Erythrophagocytosis by blast cells in B-lymphoblastic leukaemia with BCR-ABL1. | 0 |
| 33284042 | 2021 | Development of BCR-ABL1-positive ɤδ T-cell leukemia after treatment for thymoma type B1. | 0 |
| 34585520 | 2022 | Quantification of atypical BCR-ABL1 fusion transcripts in patients with chronic myeloid leukemia: Which approach for harmonization? | 0 |
| 37587772 | 2023 | One-month qRT-PCR BCR::ABL1 transcript threshold to predict early recurrence in chronic phase CML patients attempting first treatment free remission. | 0 |
| 31036315 | 2019 | BCR-ABL1 mutation screening in chronic myeloid leukaemia: is next now? | 0 |
| 37452789 | 2023 | Digital droplet PCR for T315I BCR::ABL1 KD mutation assessment in adult Ph-positive acute lymphoblastic leukemia with a minimal residual disease increase. | 0 |
| 28164528 | 2016 | Screening for BCR-ABL1 in Patients with an Isolated Eosinophilia. | 0 |
| 32237084 | 2020 | Genotype-phenotype correlation of unusual BCR-ABL1 transcripts in Philadelphia chromosome-positive leukaemia. | 0 |
Bibliography
No bibliography items were found for this article.
Summary
Note
Although the same hybrid genes issued from ABL and BCR are the hallmark of the t(9;22) translocation, this translocation may be seen in the following diseases: chronic myelogenous leukemia (CML), acute myeloid leukemia (AML), and acute lymphocytic leukemia (ALL), and will therefore be described in the 3 different situations: t(9;22)(q34;q11) in CML, t(9;22)(q34;q11) in ALL, t(9;22)(q34;q11) in AMLt(9;22)(q34;q11) in CML is herein described

t(9;22)(q34;q11) G- banding (left) - Courtesy Jean-Luc Lai and Alain Vanderhaegen (3 top) and Diane H. Norback, Eric B. Johnson, and Sara Morrison-Delap, UW Cytogenetic Services (2 bottom); R-banding (right) top: Editor; 2 others Courtesy Jean-Luc Lai and Alain Vanderhaegen); diagram and breakpoints (Editor).
Citation
Ali G Turhan
t(9;22)(q34;q11) BCR/ABL1 in CML
Atlas Genet Cytogenet Oncol Haematol. 2000-10-01
Online version: http://atlasgeneticsoncology.org/haematological/1022/t(9;22)(q34;q11)-bcr-abl1-in-cml
Historical Card
1997-12-01 t(9;22)(q34;q11) BCR/ABL1 in CML by Jean-Loup Huret,Jean-Loup Huret  Affiliation
Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France
